All In Biotech

NDA 020785 · Bristol-Myers

Thalomid

Thalidomide · Oral

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Jul 16, 1998

Approved uses

2

Original approval plus efficacy supplements

Registered trials

431

94 Phase 3, 25 recruiting

FAERS reports

36,691

32,479 serious, 12,186 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: EMBRYO-FETAL TOXICITY AND VENOUS THROMBOEMBOLISM WARNING: EMBRYO-FETAL TOXICITY AND VENOUS THROMBOEMBOLISM See full prescribing information for complete boxed warning. EMBRYO-FETAL TOXICITY • If THALOMID is taken during pregnancy, it can cause severe birth defects or embryo-fetal death. THALOMID should never be used by females who are pregnant or who could be pregnant while taking the drug. Even a single dose [1 capsule (regardless of strength)] taken by a pregnant woman during her pregnancy can cause severe birth defects. • Pregnancy must be excluded before start of treatment. Prevent pregnancy thereafter by the use of two reliable methods of contraception. ( 5.1 , 8.3 ) THALOMID is only available through a restricted distribution program, the Thalidomide REMS program ( 5.2 ). VENOUS THROMBOEMBOLISM • Significant increased risk of deep vein thrombosis (DVT) and pulmonary...

What it is approved for

From the label in effect Sep 3, 2026.

• THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM). ( 1.1 ) • THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. ( 1.2 ) 1.1 Multiple Myeloma THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM) [see Clinical Studies (14.1) ] . 1.2 Erythema Nodosum Leprosum THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence [see Clinical Studies (14.2) ].

Mechanism: The mechanism of action of THALOMID is not fully understood. Cellular activities of thalidomide are mediated through its target cereblon, a component of a cullin ring E3 ubiquitin ligase enzyme complex. THALOMID possesses immunomodulatory, anti-inflammatory and antiangiogenic properties. Available data from in vitro studies and clinical trials suggest that the immunologic effects of this compound can vary substantially under different conditions, but may be related to suppression of excessive tumor necrosis factor-alpha (TNF-α) production and down-modulation of selected cell surface adhesion...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • THALOMID · THALIDOMIDE 50MG · CAPSULE, ORAL · Prescription · TE AB
  • THALOMID · THALIDOMIDE 150MG · CAPSULE, ORAL · Prescription · TE AB
  • THALOMID · THALIDOMIDE 100MG · CAPSULE, ORAL · Prescription · TE AB
  • THALOMID · THALIDOMIDE 200MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Thalidomide" as an intervention, any sponsor and status, largest first.

All 431 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death6,421
  • disease progression2,495
  • plasma cell myeloma2,058
  • off label use1,842
  • neuropathy peripheral1,829
  • pneumonia1,716
  • fatigue1,418
  • drug ineffective1,169
  • anaemia1,026
  • asthenia1,024
  • constipation1,001
  • dyspnoea995

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20044,416
20054,279
2006809
2007769
20082,021
2009983
2010900
2011951
2012956
20131,128
20141,621
20152,888
20161,716
20171,464
20181,456
20191,520
20201,487
20211,447
20221,635
20231,454
20241,182
20251,009
2026600

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Thalomid (Thalidomide)

2024 spending

$19.8M

Beneficiaries

473

2,683 claims

Per beneficiary

$41,762

$225.16 per unit

View as table
YearSpending
2020$33,138,478
2021$28,865,933
2022$24,535,859
2023$19,395,778
2024$19,753,380

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,068 on PubMed

Sponsor: Bristol Myers Squibb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.